Therefore, DRP1 activation appears to play complex roles in both obstructive vascular remodeling as well as RVF through RV stiffening by fibrosis and cardiomyocyte dysfunction, making it a central player in the progression of the PAH disease phenotype. This evidence concerns the gene DNM1L and pulmonary arterial hypertension.